• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should monitoring of vancomycin be delayed? A case of likely nephrotoxicity occasioned by morbid obesity and minimal monitoring.

作者信息

Jones Terry E, Vasileff Hayley, Hewton Cassie

机构信息

Pharmacy Department, The Queen Elizabeth Hospital, 28 Woodville Rd, Woodville South, South Australia 5011, Australia.

出版信息

Br J Clin Pharmacol. 2012 Dec;74(6):1063-5. doi: 10.1111/j.1365-2125.2011.04006.x.

DOI:10.1111/j.1365-2125.2011.04006.x
PMID:21545484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3522820/
Abstract
摘要

相似文献

1
Should monitoring of vancomycin be delayed? A case of likely nephrotoxicity occasioned by morbid obesity and minimal monitoring.万古霉素监测是否应推迟？一例由病态肥胖和极少监测引发的可能的肾毒性病例。
Br J Clin Pharmacol. 2012 Dec;74(6):1063-5. doi: 10.1111/j.1365-2125.2011.04006.x.
2
Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.在进行治疗药物监测的患者中，谷浓度超过12.1mg/L是万古霉素相关肾毒性的主要危险因素。
Ther Drug Monit. 2014 Oct;36(5):606-11. doi: 10.1097/FTD.0000000000000061.
3
Prevention of vancomycin induced nephrotoxicity: a review of preclinical data.预防万古霉素相关性肾毒性：临床前数据的综述。
Eur J Clin Pharmacol. 2013 Apr;69(4):747-54. doi: 10.1007/s00228-012-1406-3. Epub 2012 Sep 21.
4
Vancomycin-associated renal dysfunction: where are we now?万古霉素相关的肾功能障碍：我们目前处于什么状况？
Pharmacotherapy. 2014 Dec;34(12):1259-68. doi: 10.1002/phar.1488. Epub 2014 Sep 15.
5
Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.万古霉素肾毒性的危险因素及万古霉素治疗期间肾功能的时间进程。
Eur J Clin Pharmacol. 2019 Jun;75(6):859-866. doi: 10.1007/s00228-019-02648-7. Epub 2019 Feb 15.
6
Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.重症患者初始万古霉素谷浓度与早发性万古霉素相关肾毒性之间的关系
Ther Drug Monit. 2018 Feb;40(1):109-114. doi: 10.1097/FTD.0000000000000459.
7
Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.不再是密西西比泥浆：万古霉素药代动力学剂量调整预防肾毒性的成本效益
Pharmacotherapy. 2003 May;23(5):643-50. doi: 10.1592/phco.23.5.643.32199.
8
Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents.万古霉素相关性肾毒性与联合使用肾毒性药物数量的关系。
Pharmazie. 2020 Jun 1;75(6):279-283. doi: 10.1691/ph.2020.0393.
9
Vancomycin nephrotoxicity: a review.万古霉素肾毒性：综述
J Pharm Pract. 2014 Dec;27(6):545-53. doi: 10.1177/0897190014546114. Epub 2014 Sep 28.
10
Performance of a vancomycin dosage regimen developed for obese patients.肥胖患者用万古霉素剂量方案的疗效。
Am J Health Syst Pharm. 2012 Jun 1;69(11):944-50. doi: 10.2146/ajhp110324.

本文引用的文献

1
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists.成年患者万古霉素的治疗监测：美国卫生系统药师协会、美国传染病学会和传染病药师协会的共识综述
Clin Biochem Rev. 2010 Feb;31(1):21-4.
2
Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients.氨基糖苷类药物清除率可较好地估算重症监护病房患者的肌酐清除率。
Anaesth Intensive Care. 2009 Nov;37(6):944-52. doi: 10.1177/0310057X0903700611.
3
Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.住院患者初始万古霉素浓度-时间曲线与肾毒性之间的关系。
Clin Infect Dis. 2009 Aug 15;49(4):507-14. doi: 10.1086/600884.
4
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.成人患者万古霉素的治疗监测：美国卫生系统药师协会、美国传染病学会和传染病药师协会的共识综述
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434.
5
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.更大剂量的万古霉素（至少每天4克）与肾毒性发生率增加有关。
Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. doi: 10.1128/AAC.01602-07. Epub 2008 Jan 28.
6
Selection of contrast media.造影剂的选择。
Kidney Int Suppl. 2006 Apr(100):S39-45. doi: 10.1038/sj.ki.5000373.
7
Contrast-induced nephropathy: definition, epidemiology, and patients at risk.对比剂肾病：定义、流行病学及高危患者
Kidney Int Suppl. 2006 Apr(100):S11-5. doi: 10.1038/sj.ki.5000368.
8
Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.
J Antimicrob Chemother. 2002 Nov;50(5):713-8. doi: 10.1093/jac/dkf212.
9
Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.采用贝叶斯预测技术测定肥胖对万古霉素药代动力学参数的影响。
Antimicrob Agents Chemother. 1993 Mar;37(3):436-40. doi: 10.1128/AAC.37.3.436.
10
Vancomycin pharmacokinetics in normal and morbidly obese subjects.正常和病态肥胖受试者的万古霉素药代动力学。
Antimicrob Agents Chemother. 1982 Apr;21(4):575-80. doi: 10.1128/AAC.21.4.575.